TABLE 1.

Preoperative characteristics

Zonal location	Whole cohort	TZ cancer	PZ cancer	ND and CZ cancer	P‐value*
Case number (%)	270 (100)	93 (34.4)	159 (58.9)	18 (6.7)	N/A
Age	65 (61‐69)	64 (60‐69)	66 (61‐70)	66 (60‐68.6)	.255
PSA (ng/mL)	8.15 (5.80‐11.79)	7.66 (5.70‐11.57)	8.26 (5.95‐11.31)	14.09 (6.19‐24.17)	.502
<10 (%)	172 (63.7)	65 (69.9)	100 (62.9)	7 (38.9)	.271
10‐20 (%)	72 (26.7)	19 (20.4)	47 (29.6)	6 (33.3)
>20 (%)	26 (9.6)	9 (9.7)	12 (7.5)	5 (27.8)
Clinical T stage
T1c (%)	108 (40.0)	43 (46.2)	59 (37.1)	6 (33.3)	.0265 a
T2a (%)	82 (30.4)	29 (31.2)	47 (29.6)	6 (33.3)
T2b (%)	40 (14.8)	10 (10.8)	28 (17.6)	2 (11.1)
T2c (%)	18 (6.7)	9 (9.7)	8 (5.0)	1 (5.6)
T3a (%)	17 (6.3)	2 (2.2)	14 (8.8)	1 (5.6)
T3b (%)	5 (1.9)	0 (0)	3 (1.9)	2 (11.1)
Grade group in biopsy
Grade Group 1 (%)	66 (24.4)	33 (35.5)	29 (18.2)	4 (22.2)	.0008
Grade Group 2 (%)	91 (33.7)	31 (33.3)	53 (33.3)	7 (38.9)
Grade Group 3 (%)	41 (15.2)	17 (18.3)	24 (15.1)	0 (0)
Grade Group 4 (%)	42 (15.6)	5 (5.4)	33 (20.8)	4 (22.2)
Grade Group 5 (%)	30 (11.1)	7 (7.5)	20 (12.6)	3 (16.7)
% Positive core	30 (16.7‐50)	16.7 (12.3‐34.1)	33.3 (25‐50)	51.9 (25.6‐76.7)	<.0001
History of negative biopsy (%)	30 (11.1)	17 (18.3)	10 (6.3)	3 (16.7)	.0052
NCCN risk classification
Very low/low (%)	49 (18.2)	26 (28.0)	21 (13.2)	2 (11.1)	.0043
Intermediate (%)	125 (46.3)	46 (49.5)	72 (45.3)	7 (38.9)
High (%)	78 (28.9)	18 (19.4)	55 (34.6)	5 (27.8)
Very high (%)	18 (6.7)	3 (3.2)	11 (6.9)	4 (22.2)

Continuous variables are shown in median value and interquartile range.

^a Cases are categorized into T1c/2a, 2b/2c, and 3a/3b for statistical analysis.

^* P‐values are calculated by comparison of TZ and PZ cancer.